Obstacles in prostate cancer screening: Current issues and future solutions

Benjamin Patel, Seshadri Sriprasad, Jeffrey A Cadeddu, Arron Thind, Abhay Rane

Research output: Contribution to journalArticle

Abstract

Prostate cancer is the most common cancer in men and is associated with unacceptably high mortality rates, yet an accurate and acceptable screening programme that detects clinically significant prostate cancer remains elusive. Although there is good evidence that prostate-specific antigen (PSA)-based screening lowers prostate cancer-specific mortality, especially when conducted at high intensity, the harm caused by overinvestigation, overdiagnosis and overtreatment of clinically insignificant cases arguably outweighs these benefits. Several attempts have therefore been made to improve screening, enhancing the diagnostic value of PSA and identifying novel modalities for screening. Here, we provide a comprehensive review of the benefits and harms, and analyse which of these novel screening methods show most promise. Level of evidence: 5, expert opinion.

Original languageEnglish (US)
JournalJournal of Clinical Urology
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Early Detection of Cancer
Prostatic Neoplasms
Prostate-Specific Antigen
Mortality
Expert Testimony
Neoplasms
Medical Overuse

Keywords

  • elastography
  • MRI
  • Prostate cancer
  • prostatectomy
  • PSA
  • screening

ASJC Scopus subject areas

  • Surgery
  • Urology

Cite this

Obstacles in prostate cancer screening : Current issues and future solutions. / Patel, Benjamin; Sriprasad, Seshadri; Cadeddu, Jeffrey A; Thind, Arron; Rane, Abhay.

In: Journal of Clinical Urology, 01.01.2018.

Research output: Contribution to journalArticle

Patel, Benjamin ; Sriprasad, Seshadri ; Cadeddu, Jeffrey A ; Thind, Arron ; Rane, Abhay. / Obstacles in prostate cancer screening : Current issues and future solutions. In: Journal of Clinical Urology. 2018.
@article{3be6572138094113a8ce727bbca422da,
title = "Obstacles in prostate cancer screening: Current issues and future solutions",
abstract = "Prostate cancer is the most common cancer in men and is associated with unacceptably high mortality rates, yet an accurate and acceptable screening programme that detects clinically significant prostate cancer remains elusive. Although there is good evidence that prostate-specific antigen (PSA)-based screening lowers prostate cancer-specific mortality, especially when conducted at high intensity, the harm caused by overinvestigation, overdiagnosis and overtreatment of clinically insignificant cases arguably outweighs these benefits. Several attempts have therefore been made to improve screening, enhancing the diagnostic value of PSA and identifying novel modalities for screening. Here, we provide a comprehensive review of the benefits and harms, and analyse which of these novel screening methods show most promise. Level of evidence: 5, expert opinion.",
keywords = "elastography, MRI, Prostate cancer, prostatectomy, PSA, screening",
author = "Benjamin Patel and Seshadri Sriprasad and Cadeddu, {Jeffrey A} and Arron Thind and Abhay Rane",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/2051415818815395",
language = "English (US)",
journal = "Journal of Clinical Urology",
issn = "2051-4158",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Obstacles in prostate cancer screening

T2 - Current issues and future solutions

AU - Patel, Benjamin

AU - Sriprasad, Seshadri

AU - Cadeddu, Jeffrey A

AU - Thind, Arron

AU - Rane, Abhay

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Prostate cancer is the most common cancer in men and is associated with unacceptably high mortality rates, yet an accurate and acceptable screening programme that detects clinically significant prostate cancer remains elusive. Although there is good evidence that prostate-specific antigen (PSA)-based screening lowers prostate cancer-specific mortality, especially when conducted at high intensity, the harm caused by overinvestigation, overdiagnosis and overtreatment of clinically insignificant cases arguably outweighs these benefits. Several attempts have therefore been made to improve screening, enhancing the diagnostic value of PSA and identifying novel modalities for screening. Here, we provide a comprehensive review of the benefits and harms, and analyse which of these novel screening methods show most promise. Level of evidence: 5, expert opinion.

AB - Prostate cancer is the most common cancer in men and is associated with unacceptably high mortality rates, yet an accurate and acceptable screening programme that detects clinically significant prostate cancer remains elusive. Although there is good evidence that prostate-specific antigen (PSA)-based screening lowers prostate cancer-specific mortality, especially when conducted at high intensity, the harm caused by overinvestigation, overdiagnosis and overtreatment of clinically insignificant cases arguably outweighs these benefits. Several attempts have therefore been made to improve screening, enhancing the diagnostic value of PSA and identifying novel modalities for screening. Here, we provide a comprehensive review of the benefits and harms, and analyse which of these novel screening methods show most promise. Level of evidence: 5, expert opinion.

KW - elastography

KW - MRI

KW - Prostate cancer

KW - prostatectomy

KW - PSA

KW - screening

UR - http://www.scopus.com/inward/record.url?scp=85059077547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059077547&partnerID=8YFLogxK

U2 - 10.1177/2051415818815395

DO - 10.1177/2051415818815395

M3 - Article

AN - SCOPUS:85059077547

JO - Journal of Clinical Urology

JF - Journal of Clinical Urology

SN - 2051-4158

ER -